You moron where in the hell do you think they get their $980 million in free cash flow from? Crawl back under your rock , your to stupid to even have a conversation with.
Northland Capital’s David Buck argues that Mallinckrodt’s (MNK) shares are attractive after dropping more than 15% after being likened to Valeant Pharmaceuticals International (VRX). He explains:
Our thesis on Mallinckrodt shares now trading down ~18% on media reports covering a blogger’s (negative) tweet is that see fundamental value on F2015 (reports 11-23-15) EPS of $7.25 and F2016E EPS of $7.95. Intra-day, Mallinckrodt shares trade at just 7.7x and 7.3x our fiscal year EPS forecasts for 2015/2016. Factoring in net debt of $5.1B ($42.70 per share) Mallinckrodt shares trade at an EBITDA multiple of just under 8x Fiscal 2016 which we see as positive risk-reward. Our fundamental target of $92 per share remains.
Mallinckrodt shares at initiation in mid-October and currently reflect scrutiny of the specialty pharmaceutical group and the company has indicated its F2016 outlook does not rely upon any dramatic pricing growth, particularly for its Acthar (autoimmune) and Ofirmev (acetaminophen) drugs. Mallinckrodt has also previously clarified its lack of ownership of specialty pharmacies, a recent focus of investors.
Only thing AMAG does is make new 52 week lows every week. Sold my shares yesterday for $2200.00 profit. Will buy back in around $25 There seems to be no end in sight. Sorry about your pain. Glta....
AMAG made another new 52 week low of $28.20. Well the shorts break it down to $27 or will the longs show some balls & force a short squeeze? Time will tell!
Analyst at Jefferies
Wall Street Analyst
Ranked #2,918 out of 3,871 analysts (#6,154 of 8,561 overall experts)
Can we say he sucks as a Analyst? 1 star rating, yes we can say he sucks....
Definitely going to ZERO. Feel sorry for you bag holders! Stock slides for 6 months in a roll, there something seriously wrong with this company. Hedge funds can't sell there shares fast enough.
And this coming from a fool who brought in the mid fifties. LOL... Yell baby your quit the investor!
11/17/2015 Morgan Stanley Lower Price Target from $200.00 to $98.
This junk stock will trade under $50
KaloBios Pharma (NASDAQ: KBIO) ripping higher as Martin Shkreli purchased shares.
Shkreli disclosed buying 1,211,115 shares from November 16, 2015-November 17, 2015. Prices paid ranged from $0.61-$2.43.
On November 13, 2015, KaloBios announced that it will wind down its operations and that it has engaged the Brenner Group to lead those efforts. As of June 30, 2015, KaloBios had cash, cash equivalents and investments totaling $23.2 million, but announced with the winddown it repaid in full its outstanding secured loan obligation to MidCap Financial, secured lender to the company, in the approximate amount of $6.6 million.
KBIO shares are up over 100 percent after hours. The filing is embedded below:
AMAG Pharmaceuticals, Inc. today received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for its application seeking approval for a single-dose vial of Makena (hydroxyprogesterone caproate injection) to reduce the risk of preterm birth in certain at-risk patients. A CRL is a communication from the FDA that informs companies that an application cannot be approved in its present form. In the letter, the FDA requested additional information and the company is working with its manufacturer to submit a response with the requested information to the FDA as quickly as possible.